


AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) ~~N"-Substituted 9a-N-(N' carbamoyl γ aminopropyl), 9a-N-(N' thiocarbamoyl γ aminopropyl), 9a-N-[N'-(β-cyanoethyl) N'-carbamoyl γ aminopropyl] and 9a-N-[N'-(β-cyanoethyl) N'-thiocarbamoyl γ aminopropyl] derivatives of 9-deoxy-9-dihydro-9a-aza-9a-homoerithromycin A and or 5-O-desosaminyl 9-deoxy-9-dihydro-9a-aza-9a-homoerithronolide A, novel semisynthetic macrolide antibiotics of the azalide series of the general A compound of formula 1,~~



wherein R represents H or cladinosyl moiety,

R¹ represents H or β-cyanoethyl moiety,

R² represents isopropyl, 1-naphtyl, 2-naphtyl, benzyl, 2-(trifluoromethyl)phenyl, 3-phenylpropyl, β-phenylethyl, ethoxycarbonyl-methyl, 1-(1-naphtyl)ethyl, 3,4,5-trimethoxyphenyl or a 2,4-dichlorophenyl group, and

X represents O or S,

and their acceptable addition salts thereof with inorganic or organic acids or a pharmaceutically acceptable acid addition salt thereof.

2. (Currently Amended) Substance A compound according to claim 1, characterized in that R¹ represents H, R² represents isopropyl group and X is O.
3. (Currently Amended) Substance A compound according to claim 1, characterized in that R¹ represents H, and R² represents 1-naphthyl group and X is O.
4. (Currently Amended) Substance A compound according to claim 1, characterized in that R¹ represents H and R² represents 2-naphthyl group and X is O.
5. (Currently Amended) Substance A compound according to claim 1, characterized in that R¹ represents H and R² represents benzyl group and X is O.
6. (Currently Amended) Substance A compound according to claim 1, characterized in that R¹ represents H and R² represents 2-(trifluoromethyl) phenyl group and X represents O.
7. (Currently Amended) Substance A compound according to claim 1, characterized in that R¹ represents H and R² represents 3-phenylpropyl group and X is S.
8. (Currently Amended) Substance A compound according to claim 1, characterized in that R¹ represents H and R² represents β-phenylethyl group and X is S.
9. (Currently Amended) Substance A compound according to claim 1, characterized in that R¹ represents H and R² represents ethoxycarbonylmethyl group and X is O.

10. (Currently Amended) Substance A compound according to claim 1, characterized in that R¹ represents H and R² represents 1-(1-naphthyl)ethyl group and X is O.
11. (Currently Amended) Substance A compound according to claim 1, characterized in that R¹ represents H and R² represents 3,4,5-trimethoxyphenyl group and X is O.
12. (Currently Amended) Substance A compound according to claim 1, characterized in that R¹ represents H and R² represents 2,4-dichlorophenyl group and X is O.
13. (Currently Amended) Substance A compound according to claim 1, characterized in that R¹ represents H and R² represents benzyl group or 1-naphthyl group and X is S.

Claims 14 – 19 (Canceled)

20. (Currently Amended) Substance A compound according to claim 1, characterized in that R¹ represents β-cyanoethyl group, R² represents 3-phenylpropyl group and X is S.
21. (Currently Amended) Substance A compound according to claim 1, characterized in that R¹ represents β-cyanoethyl group, R² represents β-phenylethyl group and X is S.


Claims 22 - 24 (Canceled)

25. (Currently Amended) Substance A compound according to claim 1, characterized in that R¹ represents β-cyanoethyl group, R² represents 2,4-dichlorophenyl group and X is O.

Claims 26 – 53 (Canceled)

54. (Currently Amended) Process for the preparation of ~~N"-substituted 9a-N-(N'-carbamoyl γ-aminopropyl), 9a-N-(N'-thiocarbamoyl γ-aminopropyl), 9a-N-[N'-(β-cyanoethyl)-N'-carbamoyl γ-aminopropyl] and 9a-N-[N'-(β-cyanoethyl)-N'-thiocarbamoyl γ-aminopropyl] derivatives of 9-deoxy-9-~~

~~dihydro-9a-aza-9a-homoerithromycin A and or 5-O-desosaminyl-9-deoxy-9-dihydro-9a-aza-9a-homoerithronolide A, a compound of the general formula 1,~~




wherein R represents H or cladinosyl moiety,

R¹ represents H or β-cyanoethyl moiety,

R² represents isopropyl, 1-naphtyl, 2-naphtyl, benzyl, 2-(trifluoromethyl)phenyl, 3-phenylpropyl, β-phenylethyl, ethoxycarbonylmethyl, 1-(1-naphtyl)ethyl, 3,4, 5-trimethoxyphenyl and 2,4-dichlorophenyl group, and

X represents O or S,

characterized in that ~~9a-N-(γ-aminopropyl) and or 9a-N-[N'-(β-cyanoethyl)-γ-aminopropyl] derivatives of 9-deoxy-9-dihydro-9a-aza-9a-homoerithromycin A and or 5-O-desosaminyl-9-deoxy-9-dihydro-9a-aza-9a-homoerithronolide A generally a compound of formula 2,~~




2

wherein R represents H or a cladinosyl group and

R¹ represents H or a β -cyanoethyl group

is reacted with isocyanates or isothiocyanates of general formula 3



wherein R² represents isopropyl, 1-naphtyl, 2-naphtyl, benzyl, 2-(trifluoromethyl) phenyl, 3-phenylpropyl, (3-phenylethyl β-phenylethyl, ethoxycarbonyl- methyl, 1-(1-naphtyl)ethyl, 3,4, 5-trimethoxyphenyl and or 2,4-dichlorophenyl group, and

X represents O or S,

in toluene, xylene or some others aprotic solvents at a temperature 0° -110° C and then, if appropriate, to a reaction with inorganic or organic acids.

55. (Currently amended) A Pharmaceutical compositions comprising a pharmaceutically acceptable carrier and an antibacterially effective amount of the a substance compound according to claim 1.

56. (Canceled)

57. (Currently amended) A method of treating bacterial infections in a mammal comprising administering to such mammal an antibacterially effective amount of the a substance compound of formula 1 according to claim 1.

58. (Currently amended) The method according to claim 57, wherein R¹ of a compound of formula 1 represents H.

59. (Currently amended) The method according to claim 57, wherein R² of a compound of formula 1 represents a 1-naphthyl, 2-naphthyl, 1-(1-naphtyl)ethyl, or 2,4-dichlorophenyl group.

60. (New) The method according to claim 57 wherein the mammal is a human.